Namiki Izumi
#154,516
Most Influential Person Now
Researcher
Namiki Izumi's AcademicInfluence.com Rankings
Namiki Izumicomputer-science Degrees
Computer Science
#8390
World Rank
#8822
Historical Rank
Machine Learning
#3422
World Rank
#3465
Historical Rank
Artificial Intelligence
#3723
World Rank
#3778
Historical Rank
Database
#5403
World Rank
#5607
Historical Rank
Download Badge
Computer Science
Namiki Izumi's Degrees
- PhD Computer Science Imperial University of Japan
- Masters Computer Science Imperial University of Japan
- Bachelors Computer Science Imperial University of Japan
Similar Degrees You Can Earn
Why Is Namiki Izumi Influential?
(Suggest an Edit or Addition)Namiki Izumi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C (2009) (1815)
- Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. (1996) (1049)
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version (2011) (749)
- Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. (1995) (683)
- Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection (2014) (538)
- JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan (2014) (515)
- Mapping the human genetic architecture of COVID-19 (2021) (455)
- Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines) (2015) (368)
- Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. (2015) (344)
- Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. (2016) (341)
- Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update (2019) (320)
- Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. (2013) (314)
- Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial (2019) (298)
- Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. (2016) (297)
- Branched‐chain amino acids as pharmacological nutrients in chronic liver disease (2011) (275)
- Influence of hepatitis B virus genotypes on the intra‐ and extracellular expression of viral DNA and antigens (2006) (272)
- Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection (2010) (267)
- 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. (2018) (227)
- α‐fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C (2013) (220)
- Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial (2014) (195)
- Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update (2014) (189)
- Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. (2012) (177)
- Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon‐β therapy (1997) (173)
- Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. (2018) (170)
- Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function (2017) (162)
- Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study (2019) (156)
- Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis (1992) (154)
- Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update (2021) (154)
- Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. (2014) (145)
- Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment (1995) (145)
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma (2013) (143)
- Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. (2018) (143)
- Prognostic Impact of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma: An Analysis of 1160 Cases From a Nationwide Survey (2014) (139)
- Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. (2003) (139)
- Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean (2012) (135)
- Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. (2006) (132)
- Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation (2001) (127)
- Distribution of Hepatitis B Virus Genotypes among Patients with Chronic Infection in Japan Shifting toward an Increase of Genotype A (2009) (124)
- A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. (2015) (123)
- Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. (2011) (122)
- Report of the 19th follow‐up survey of primary liver cancer in Japan (2016) (122)
- Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan (2015) (119)
- Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan (2013) (118)
- Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey (2017) (115)
- Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. (2005) (114)
- Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan (2016) (105)
- Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies (2014) (103)
- Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan (2010) (102)
- Report of the 20th Nationwide follow‐up survey of primary liver cancer in Japan (2020) (101)
- Effect of vitamin K2 on the recurrence of hepatocellular carcinoma (2011) (101)
- REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset (2019) (99)
- Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. (2018) (98)
- Increased gene expression of water channel in cirrhotic rat kidneys (1995) (94)
- Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B (1996) (90)
- Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study (2009) (89)
- Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. (2017) (89)
- Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization (2001) (85)
- JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2 (2016) (85)
- Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan (2010) (85)
- Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. (2011) (82)
- Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection (1999) (81)
- Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures (2019) (79)
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma (2011) (78)
- Surveillance and Diagnostic Algorithm for Hepatocellular Carcinoma Proposed by the Liver Cancer Study Group of Japan: 2014 Update (2014) (76)
- Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study (2014) (72)
- Liver Cancer Working Group report. (2010) (72)
- Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. (2003) (71)
- Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. (2006) (69)
- Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy (2010) (67)
- Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. (2004) (67)
- Interferon Therapy for Chronic Hepatitis C in Hemodialysis Patients: Increased Serum Levels of Interferon (1998) (65)
- A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis (2010) (65)
- Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma (2013) (63)
- Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response (2012) (62)
- Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation (2011) (62)
- A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation (2018) (61)
- Nationwide Study of 4741 Patients With Non-B Non-C Hepatocellular Carcinoma With Special Reference to the Therapeutic Impact (2014) (60)
- A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high‐dose daily interferon alfa plus ribavirin and intravenous twice‐daily treatment with interferon beta (2001) (60)
- T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. (2006) (58)
- Simeprevir (TMC435) once daily with peginterferon‐α‐2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO‐4 study (2015) (56)
- Wisteria floribunda agglutinin positive human Mac‐2‐binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients (2015) (55)
- Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease. (2003) (54)
- Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. (2001) (54)
- Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma (2019) (52)
- Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey (2017) (52)
- Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan (2019) (52)
- Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method (2018) (52)
- Association of IL28B variants with response to pegylated‐interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b (2011) (49)
- Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm (2013) (49)
- L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. (2015) (49)
- Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group (2018) (47)
- Influence of Hepatitis B Virus X and Core Promoter Mutations on Hepatocellular Carcinoma among Patients Infected with Subgenotype C2 (2007) (47)
- Genome-wide association study identified ITPA / DDRGK 1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C (2011) (46)
- Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey. (2020) (46)
- Diagnostic and Treatment Algorithm of the Japanese Society of Hepatology: A Consensus-Based Practice Guideline (2010) (46)
- Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (2020) (45)
- Impact of Histologically Confirmed Lymph Node Metastases on Patient Survival After Surgical Resection for Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey (2014) (45)
- Noninvasive estimation of fibrosis progression overtime using the FIB‐4 index in chronic hepatitis C (2013) (44)
- Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. (2008) (44)
- Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon‐alpha plus ribavirin combination therapy (2005) (44)
- Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. (2013) (42)
- Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. (2015) (42)
- Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients (2014) (42)
- No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations (2012) (42)
- Naturally occurring, resistance‐associated hepatitis C virus NS5A variants are linked to interleukin‐28B genotype and are sensitive to interferon‐based therapy (2015) (41)
- Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate (2019) (41)
- Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON (2016) (40)
- Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. (2019) (40)
- Relationship between Polymorphisms of the Inosine Triphosphatase Gene and Anaemia or Outcome after Treatment with Pegylated Interferon and Ribavirin (2011) (40)
- Hepatocellular carcinoma risk assessment using gadoxetic acid‐enhanced hepatocyte phase magnetic resonance imaging (2014) (40)
- Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group (2018) (39)
- Virological Escape in HCV Genotype-1-Infected Patients Receiving Daclatasvir plus Ribavirin and Peginterferon Alfa-2A or Alfa-2B (2014) (39)
- Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma (2020) (38)
- Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial. (2018) (38)
- B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial (2019) (38)
- Sequential changes in full-length genomes of hepatitis B virus accompanying acute exacerbation of chronic hepatitis B. (1996) (38)
- Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis (2016) (38)
- Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals (2018) (38)
- A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). (2019) (38)
- Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis (2011) (38)
- Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma (2019) (38)
- Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial (2014) (37)
- Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma (2018) (37)
- Case–control study for the identification of virological factors associated with fulminant hepatitis B (2009) (37)
- Wisteria floribunda agglutinin‐positive Mac‐2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct‐acting antivirals for hepatitis C virus (2018) (36)
- No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection (2018) (36)
- Quantification of collagen and elastic fibers using whole‐slide images of liver biopsy specimens (2013) (36)
- The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. (2008) (36)
- LecT‐hepa, a glyco‐marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients (2012) (36)
- Up‐to‐seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child–Pugh grade deterioration after initial conventional transarterial chemoembolization (2018) (36)
- Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. (2012) (35)
- Resistance Analyses of Japanese Hepatitis C‐Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies (2016) (35)
- Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites (2016) (35)
- Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure (2016) (35)
- Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early‐stage hepatocellular carcinoma (2014) (35)
- Roles of alcohol, hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. (1996) (35)
- Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma (2016) (34)
- Hepatitis C virus infection in alcoholic liver cirrhosis in Japan: its contribution to the development of hepatocellular carcinoma. (1993) (34)
- Intrahepatic mRNA expression of interferon‐inducible antiviral genes in liver diseases: dsRNA‐dependent protein kinase overexpression and RNase L inhibitor suppression in chronic hepatitis C (2000) (34)
- Lymphocyte cytotoxicity for autologous human hepatocytes in alcoholic liver disease. (1983) (34)
- Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan (2015) (33)
- Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis (2016) (33)
- Role of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced Magnetic Resonance Imaging in the Management of Hepatocellular Carcinoma: Consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan (2013) (33)
- New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia (2014) (33)
- Daclatasvir Combined with Peginterferon Alfa-2A and Ribavirin in Japanese Patients Infected with Hepatitis C Genotype 1 (2014) (32)
- Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers (2013) (32)
- Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection (2015) (32)
- Hepatic iron contents and response to interferon-α in patients with chronic hepatitis C (1996) (31)
- Response criteria of tolvaptan for the treatment of hepatic edema (2018) (31)
- Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C (2014) (30)
- Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double‐blind, controlled trial (2017) (30)
- 2011 Japanese Society for Dialysis Therapy Guidelines for the Treatment of Hepatitis C Virus Infection in Dialysis Patients (2012) (30)
- Prospective comparison of real‐time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients (2014) (29)
- Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-alpha-mediated apoptosis in Huh7 cells. (2003) (29)
- Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice (2019) (29)
- Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography. (2003) (29)
- Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma (2018) (28)
- Non‐alcoholic fatty liver disease fibrosis score and FIB‐4 scoring system could identify patients at risk of systemic complications (2015) (28)
- Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting (2018) (28)
- Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease (2017) (28)
- Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice (2021) (27)
- Report of the 21st Nationwide Follow‐up Survey of Primary Liver Cancer in Japan (2010–2011) (2020) (27)
- Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis. (2014) (26)
- Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group (2018) (26)
- Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009 (2011) (26)
- Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan. (2020) (26)
- Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts (2008) (26)
- Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013) (2021) (26)
- The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study (2021) (25)
- Time-related changes in full-length hepatitis C virus sequences and hepatitis activity. (1999) (25)
- Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real‐life setting in Japan (2010) (25)
- Validation of Three Staging Systems for Hepatocellular Carcinoma (JIS Score, Biomarker-Combined JIS Score and BCLC System) in 4,649 Cases from a Japanese Nationwide Survey (2014) (25)
- Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio (2017) (24)
- Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease (2019) (24)
- Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study (2014) (24)
- Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan (2014) (24)
- Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. (2003) (24)
- Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy (2015) (24)
- Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis (2011) (23)
- Sequences in the interferon sensitivity‐determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG‐interferon plus ribavirin: Data mining analysis (2011) (23)
- Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection (2019) (23)
- Hypouricemia and Hyperuricosuria as Expressions of Renal Tubular Damage in Primary Biliary Cirrhosis (2007) (23)
- New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode (2019) (23)
- Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study (2012) (22)
- Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B (2010) (22)
- Mechanism of increased hepatotoxicity of acetaminophen by the simultaneous administration of caffeine in the rat. (1989) (22)
- Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct‐acting antivirals (2019) (22)
- Changes of HCV quasispecies during combination therapy with interferon and ribavirin. (2004) (22)
- Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey (2017) (21)
- Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients (2012) (21)
- JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis (2020) (21)
- Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. (1996) (21)
- TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). (2021) (21)
- Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. (2010) (21)
- Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha‐2b and ribavirin (2007) (21)
- Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases (2021) (21)
- Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial) (2021) (21)
- Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan (2019) (21)
- Cancer preventive effect of pegylated interferon α‐2b plus ribavirin in a real‐life clinical setting in Japan: PERFECT interim analysis (2011) (20)
- Hepatitis B surface antigen reduction by switching from long‐term nucleoside/nucleotide analogue administration to pegylated interferon (2017) (20)
- Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection (2018) (20)
- Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens (2015) (20)
- Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C (2010) (20)
- Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis (2020) (20)
- Non‐invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection (2018) (20)
- Differential gene-expression profiles associated with gastric adenoma (2004) (20)
- Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality (2021) (20)
- DOCK2 is involved in the host genetics and biology of severe COVID-19 (2022) (20)
- Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus‐1b: No association with efficacy of interferon therapy or serum HCV‐RNA levels (1997) (20)
- Recent advances of radiofrequency ablation for early hepatocellular carcinoma (2011) (20)
- Prospective Randomized Controlled Phase III Trial Comparing the Efficacy of Sorafenib versus Sorafenib in Combination with Low-Dose Cisplatin/Fluorouracil Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma (2016) (19)
- A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma (2020) (19)
- Clinical significance of serum antibodies against alcohol-altered hepatocyte membrane in alcoholic liver disease. (1989) (19)
- Detection and analysis of replicating hepatitis C virus RNA in hepatocellular carcinoma tissues. (1995) (19)
- Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib (2020) (19)
- Limited usage of T‐Cell receptor β chains and sequences of the complementarity determining region 3 of lymphocytes infiltrating in the liver of autoimmune hepatitis (1995) (19)
- Differential effect of interferon on hepatitis C virus 1b quasispecies in the nonstructural protein 5A gene. (1999) (19)
- Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan. (2013) (19)
- Serum antibodies against alcohol-treated rabbit hepatocytes in patients with alcoholic liver disease. (1985) (19)
- Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib (2015) (19)
- Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures (2019) (19)
- Complete nucleotide sequences of hepatitis B virus genomes associated with epidemic fulminant hepatitis (1996) (18)
- Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. (2003) (18)
- A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96 (2017) (18)
- Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors (2010) (18)
- Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial (2019) (18)
- Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. (2018) (18)
- Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease (2021) (18)
- Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy (2015) (18)
- Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. (2022) (18)
- LAPAROSCOPIC RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA (2007) (18)
- Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography. (2019) (17)
- Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. (2003) (17)
- Hemolysis, elevated liver enzymes, and low platelets syndrome associated with primary anti-phospholipid antibody syndrome. (1997) (17)
- Demonstration of quality of care measurement using the Japanese liver cancer registry (2011) (17)
- Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat. (1985) (17)
- Overexpression of interferon γ-inducible protein 10 in the liver of patients with type i autoimmune hepatitis identified by suppression subtractive hybridization (2001) (16)
- Value of Highly Sensitive Fucosylated Fraction of Alpha-Fetoprotein for Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment (2013) (16)
- Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma (2019) (16)
- Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group (2019) (16)
- Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog (2020) (16)
- Reduced Organic Anion Transporter Expression Is a Risk Factor for Hepatocellular Carcinoma in Chronic Hepatitis C Patients: A Propensity Score Matching Study (2014) (15)
- [High-sensitivity C-reactive protein (hs-CRP): a promising biomarker for the screening of non-alcoholic steatohepatitis (NASH)]. (2006) (15)
- Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment (2016) (15)
- Impact of resistance‐associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir (2017) (15)
- Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C (2011) (15)
- Irregular vascular pattern by contrast‐enhanced ultrasonography and high serum Lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early‐stage hepatocellular carcinoma (2016) (15)
- Quantitative immunohistochemical analysis of lymphocyte subsets in alcoholic liver disease (1993) (15)
- A case of primary leiomyoma of the liver in a patient without evidence of immunosuppression. (2002) (15)
- A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results (2016) (15)
- Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. (2005) (14)
- A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival. (2021) (14)
- Multicenter Study of Pegylated Interferon α‐2a Monotherapy for Hepatitis C Virus‐Infected Patients on Hemodialysis: REACH Study (2014) (14)
- Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model (2010) (14)
- Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma (2017) (14)
- Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b (2013) (14)
- Ultrasonography and Computed Tomography in Adenomyomatosis of the Gallbladder (1985) (14)
- Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma (2015) (14)
- Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B (2020) (14)
- Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma (2012) (13)
- Use of microwave coagulation therapy in liver transplant candidates with hepatocellular carcinoma: a preliminary report. (2001) (13)
- Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. (2021) (13)
- Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. (2019) (13)
- Rapid Decrease of Plasma HCV RNA in Early Phase of Twice Daily Administration of 3 MU Doses Interferon-β in Patients with Genotype 1b Hepatitis C Infection (2001) (13)
- Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir (2019) (13)
- Systemic hypotension and diuresis by L‐arginine in cirrhotic patients with ascites: Role of nitric oxide (1995) (13)
- Hepatic IFNL4 expression is associated with non‐response to interferon‐based therapy through the regulation of basal interferon‐stimulated gene expression in chronic hepatitis C patients (2017) (12)
- A multicenter survey of re‐treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan (2013) (12)
- Development of Hepatocellular Carcinoma after Interferon Therapy in Chronic Hepatitis C (2005) (12)
- Use of simeprevir following pre‐emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12‐week pilot study (2015) (12)
- Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group (2016) (12)
- A Comparison of the Exponential Decay Slope between PEG-IFN alfa-2b/Ribavirin and IFN alfa-2b/Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Genotype 1b Infection and a High Viral Load (2004) (12)
- Polymerase Domain B Mutation Is Associated with Hepatitis Relapse during Long-Term Lamivudine Therapy for Chronic Hepatitis B (2005) (12)
- Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated‐interferon plus ribavirin therapy for chronic hepatitis C (2013) (12)
- Efficacy of daclatasvir in hepatitis C virus (2014) (12)
- Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort. (2021) (12)
- Investigation of Anti-SARS-CoV-2 IgG and IgM Antibodies in the Patients with COVID-19 by Three Different ELISA Test Kits (2020) (12)
- Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan (2021) (12)
- Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis (2021) (11)
- Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C (2015) (11)
- Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis (2015) (11)
- Clinical validation of an immunochromatographic SARS‐Cov‐2 IgM/IgG antibody assay with Japanese cohort (2020) (11)
- Effects of HLA-DPB1 genotypes on chronic hepatitis B infection in Japanese individuals. (2015) (11)
- Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection. (2003) (11)
- 1193 A DESCRIPTION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH DACLATASVIR (BMS-790052) IN COMBINATION WITH RIBAVIRIN AND PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B (2012) (11)
- Systemic hypotension and diuresis by L-arginine in cirrhotic patients with ascites: role of nitric oxide. (1995) (11)
- External validation of FIB‐4: Diagnostic accuracy is limited in elderly populations (2007) (11)
- Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis (2018) (11)
- A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan (2009) (11)
- A multicenter nonrandomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF cohort trial). (2019) (10)
- Age and Total Ribavirin Dose are Independent Predictors of Relapse after Interferon Therapy in Chronic Hepatitis C Revealed by Data Mining Analysis (2012) (10)
- Overexpression of interferon gamma-inducible protein 10 in the liver of patients with type I autoimmune hepatitis identified by suppression subtractive hybridization. (2001) (10)
- Clinical benefit of peretinoin for the suppression of hepatocellular carcinoma (HCC) recurrence in patients with Child-Pugh grade A (CP-A) and small tumor: A subgroup analysis in a phase II/III randomized, placebo-controlled trial. (2011) (10)
- Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy (2005) (10)
- Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients (2019) (10)
- Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease. (2021) (10)
- Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near‐infrared spectroscopy (2014) (10)
- ITPA genetic variants influence efficacy of PEG‐IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type (2014) (9)
- Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma (2022) (9)
- A prospective study on hepatocellular carcinoma in liver cirrhosis: respective roles of alcohol and hepatitis C virus infection. (1994) (9)
- Pegylated Interferon-Associated Retinopathy in Chronic Hepatitis C Patients (2006) (9)
- Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study. (2001) (8)
- [Long time oral supplementation with branched-chain amino acids improves survival and decreases recurrences in patients with hepatocellular carcinoma]. (2008) (8)
- Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients (2020) (8)
- Laparoscopic ablation therapy for hepatocellular carcinoma. Clinical significance of a newly developed laparoscopic sector ultrasonic probe (2003) (8)
- Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease (2021) (8)
- Early hepatocellular carcinoma as a signaling lesion for subsequent malignancy. (2016) (8)
- Current Status of Hepatocellular Carcinoma Treatment in Japan (2012) (8)
- The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study (2016) (7)
- Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen (2019) (7)
- 82 ASSOCIATION BETWEEN IL28B GENE VARIATION AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA AFTER INTERFERON THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C (2011) (7)
- Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score (2020) (7)
- CD81 nucleotide mutation in hepatocellular carcinoma and lack of CD81 polymorphism in patients at stages of hepatitis C virus infection (2001) (7)
- Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group (2021) (7)
- Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma (2022) (7)
- Direct acting antivirals did not increase early recurrences after curative treatment of HCV related hepatocellular carcinoma in comparison with IFN-based treatment (2017) (7)
- Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity (2020) (7)
- Characteristics of anti-HCV antibody-positive patients with hepatocellular carcinoma on chronic hemodialysis: recommendation of periodic ultrasonography for early detection. (1996) (7)
- Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup (2020) (7)
- Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. (2020) (7)
- Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin (2012) (7)
- Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients (2001) (7)
- Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B (2013) (7)
- Superiority of Avatrombopag to Placebo in Increasing Platelet Counts in Patients with Chronic Liver Disease-Associated Thrombocytopenia Undergoing Scheduled Procedures: Results from 2, Phase 3 Randomized Studies (2017) (7)
- Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation (2021) (6)
- Hepatitis B core‐related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen‐negative chronic hepatitis B patients (2021) (6)
- Diagnostic accuracy of two-dimensional shear wave elastography for liver fibrosis: a multicenter prospective study. (2021) (6)
- Changes of liver stiffness measured by magnetic resonance elastography during direct‐acting antivirals treatment in patients with chronic hepatitis C (2020) (6)
- The dynamics of quantitative SARS‐CoV‐2 antispike IgG response to BNT162b2 vaccination (2021) (6)
- Pretreatment Gastric Lavage Reduces Postoperative Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms (2016) (6)
- Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma (2022) (6)
- Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy (2011) (6)
- G06 : A randomized, double-blind, placebo-controlled phase III trial of TSU-68 (orantinib) combined with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma (2015) (6)
- [A clinical trial of transarterial chemoembolization for hepatocellular carcinoma using 4'-0-tetrahydropyranyladriamycin]. (1990) (6)
- The evolutionary patterns of hepatitis C virus subtype 2a and 6a isolates linked to an outbreak in China in 2012. (2015) (5)
- Prognosis of intrahepatic cholangiocarcinoma stratified by albumin–bilirubin grade (2021) (5)
- Possible involvement of protein kinase C and calcium in GSH efflux from Hep G2 cells. (1992) (5)
- Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: A multicenter study (2013) (5)
- Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy (2020) (5)
- Serum HBV RNA as a possible marker of HBV replication in the liver during nucleot(s)ide analogue therapy (2013) (5)
- P933 ONCE-DAILY ORAL LUSUTROMBOPAG, ALTERNATIVE TO PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING RADIOFREQUENCY ABLATION: RESULTS FROM A PHASE 2B, RANDOMIZED, DOUBLE-BLIND STUDY (2014) (5)
- Two-step strategy, FIB-4 followed by magnetic resonance elastography, for detecting advanced fibrosis in NAFLD. (2022) (5)
- Treatment for advanced hepatocellular carcinoma by transarterial chemotherapy using reservoirs or one-shot arterial chemotherapy. (1997) (5)
- Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-Fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor (2020) (5)
- Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma (2022) (5)
- Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL) (2019) (5)
- Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C (2020) (5)
- Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment (2021) (5)
- Enhancement of mitochondrial gene expression in the liver of primary biliary cirrhosis. (2005) (4)
- Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib (2020) (4)
- Analysis of Patient Outcome after Non-curative Resection for Hepatocellular Carcinoma Using Nationwide Survey Data in Japan (2020) (4)
- Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. (2021) (4)
- IDDF2019-ABS-0168 Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) (2019) (4)
- Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers (2014) (4)
- Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. (2015) (4)
- Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. (2020) (4)
- [A case of autoimmune hepatitis associated with anti-phospholipid antibody syndrome]. (1997) (4)
- Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag (2021) (4)
- The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force (2022) (3)
- Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study. (2019) (3)
- Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic Hepatitis B Patients: A Global Phase 3 Study (2017) (3)
- IDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB) (2020) (3)
- [A case of fulminant type of dermatomyositis, associated with acute renal failure (author's transl)]. (1980) (3)
- Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus‐related liver cirrhosis: A multicenter retrospective study in Japan (2014) (3)
- Is platelet monitoring during 7‐day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open‐label study (2020) (3)
- Improved survival in patients with hepatocellular carcinoma over 30 years in Japan: Analysis of nationwide prospective registry of 148,161 patients. (2011) (3)
- 1169 GENETIC POLYMORPHISM IN IL28B PREDICTS NULL VIROLOGICAL RESPONSE TO PEGYLATED-INTERFERON PLUS RIBAVIRIN THERAPY FOR CHRONIC HEPATITIS C (2010) (3)
- A CASE OF FULMINANT TYPE OF DERMATOMYOSITIS, ASSOCIATED WITH ACHUTE RENAL FAILURE (1980) (3)
- Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis (2021) (3)
- Repeated radiofrequency ablation for the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long‐term survival (2007) (3)
- Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study (2022) (3)
- Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region (2023) (3)
- PS-180-ns5a resistance profile of genotype 1b virological failures that impacts outcome of re-treatment by glecaprevir/pibrentasvir: Nation-wide real world study (2019) (2)
- IDDF2018-ABS-0105 No resistance to TENOFOVIR ALAFENAMIDE detected through 96 weeks of treatment in patients with chronic hepatitis B (2018) (2)
- Management of ascites in cirrhotic patients. (2017) (2)
- Radiofrequency Tumor Ablation for Hepatocellular Carcinoma (2002) (2)
- Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma (2022) (2)
- Retreatment with Peginterferon α-2a + Ribavirin in Patients Who Failed Previous Peginterferon α-2b + Ribavirin Combination Therapy (2012) (2)
- [A case of pancreatic pleural effusion and ascites treated successfully with conservative measures including octreotide and nafamostat mesilate]. (1996) (2)
- Cytochrome P450 2C19 (CYP2C19) genotype status is not associated with cure rates of dual therapy with rabeprazole and amoxicillin for Helicobacter pylori (2001) (2)
- Genome-Wide Association Study Identi fi es TLL 1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection (2017) (2)
- Corrigendum to: “Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey” [J Hepatol 2013;58:724–729] (2013) (2)
- 1178 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES IL28B ASSOCIATED WITH RESPONSE TO PEGYLATED INTERFERON-ALFA AND RIBAVIRIN THERAPY FOR JAPANESE PATIENTS WITH CHRONIC HEPATITIS C (2010) (2)
- Treatment Guidelines of Hepatitis C (2012) (2)
- Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study (2023) (2)
- Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey (2021) (2)
- Prognostic grade for resecting hepatocellular carcinoma: multicentre retrospective study. (2021) (2)
- V1-receptor mediated GSH efflux by vasopressin from rat hepatocytes. (1992) (2)
- Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC). (2020) (2)
- [Phenobarbital and diphenylhydantoin in the plasma and phenobarbital in the cerebrospinal fluid. I. Studies on the concurrent determination of phenobarbital and diphenylhydantoin in the plasma by ultraviolet spectrophotometry and its clinical application]. (1970) (2)
- Hepatitis B virus mutations associated with lamivudine therapy in patients with chronic hepatitis B (1999) (2)
- FGF3/FGF4 Amplification and Multiple Lung Metastases in Responders to Sorafenib in Hepatocellular Carcinoma (2013) (2)
- Two cases of hepatic angiomyolipoma with different ultrasonographic and radiographic findings (2008) (2)
- Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials (2020) (2)
- Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy (2022) (2)
- Characteristics and Outcomes of HCV Genotype-1-Infected Patients Treated with Peginterferon and Ribavirin Combination Therapy with Discordant HCV Responses 4 and 12 Weeks after Starting Therapy (2014) (2)
- The interferon sensitivity determining region in the era of combination therapies and the rational use of such therapies for patients with HCV genotype 1b infection. (2003) (2)
- Hypouricemia and renal tubular acidosis in primary biliary cirrhosis (1985) (2)
- Chronic hepatitis in alcoholics: Two cases with alcohlic liver disease whose liver biopsies showed decrease of inflammatory activity after abstinence. (1988) (2)
- Sustained virologic response by ledipasvir/sofosbuvir reduces the incidence of hepatocellular carcinoma in Japanese patients with HCV genotype 1 infection. - Comparison with Simeprevir with peginterferon plus ribavirin (2017) (2)
- Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus (2021) (2)
- Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment (2022) (2)
- Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C (2014) (2)
- Multi-center clinical studies for strategies to improve patients' accessibility to peginterferon therapy: Consideration based on both prospective study and retrospective study (2010) (2)
- Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion: A Japanese nationwide survey. (2016) (2)
- Peginterferon ALPHA-2A (40KD) Plus Ribavirin for the Treatment of Patients With Chronic Hepatitis C (CHC) and Compensated Liver Cirrhosis in Japan (2011) (2)
- Whole Slide Image Analysis System for Quantification of Liver Fibrosis (2014) (1)
- Tolvaptan for the Treatment of Refractory Ascites (2016) (1)
- [Noninvasive Estimation of Liver Fibrosis and Hepatocellular Carcinoma Development Using WFA(+)-M2BP in Chronic Hepatitis C Patients]. (2015) (1)
- Pseudomonas paralcaligenes sp. nov., isolated from a hospitalized patient. (2023) (1)
- PF699 LUSUTROMBOPAG IS A SAFE TREATMENT OPTION FOR THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING A SCHEDULED INVASIVE PROCEDURE: POOLED SAFETY ANALYSIS FROM 3 STUDIES (2019) (1)
- Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease (2021) (1)
- IDDF2018-ABS-0110 Efficacy and safety of SOFOSBUVIR/VELPATASVIR plus RIBAVIRIN for 12 or 24 weeks in genotype 1 or 2 HCV-INFECTED japanese patients with prior treatment failure to daa-based regimens (2018) (1)
- A case of autoimmune hepatitis associated with polyglandular syndrome. (1997) (1)
- Correction: Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma (2016) (1)
- Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL) (2022) (1)
- Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B (2022) (1)
- Hepatitis C viral dynamics in serum and the target cell during high-dose daily interferon-α with ribavirin combination therapy and twice-a-day interferon-β therapy (2001) (1)
- A multicenter, non-randomized, controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF-Cohort Trial): Analysis of overall survival. (2022) (1)
- 1171 IDENTIFICATION OF GENETIC VARIANTS OF THE IL28B ASSOCIATED WITH SPONTANEOUS CLEARANCE OF HEPATITIS C VIRUS IN JAPANESE POPULATION (2010) (1)
- SAT-002-Lusutrombopag is a safe treatment option for thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure: Pooled safety analysis from 3 studies (2019) (1)
- Optimal timing of interferon treatment for acute hepatitis C. (2006) (1)
- 582 High response rates with peginter-feron α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in Japanese non-responders or relapsers to conventional interferon (2006) (1)
- No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy. (2022) (1)
- Myopenia as a significant prognostic factor in BCLC-B intermediate-stage hepatocellular carcinoma treated with sorafenib. (2019) (1)
- Hyperglycemia is a Significant Risk Factor for Recurrence of Hepatocellular Carcinoma After Curative Ablation Therapy and Related to Poor Survival (2011) (1)
- Cytotoxic T-cell response to acetaldehyde-pulsed cells in alcoholic liver disease. (1988) (1)
- Erratum to: Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers (2013) (1)
- [A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection]. (2015) (1)
- Repression of HCV-IRES-dependent protein translation by the activation of PKR with dsRNA (2000) (1)
- Urinary polyamine excretion measured by a simple enzymatic method is clinically useful as an expression of hepatic regeneration in liver diseases. (1990) (1)
- Sofosbuvir–velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan (2022) (1)
- [A case of von Recklinghausen's disease complicated by adenocarcinoma of the papilla of Vater]. (1997) (1)
- [Triple therapy with direct acting antiviral agent, peginterferon and ribavirin for chronic hepatitis C]. (2012) (1)
- A case of unresectable hepatocellular carcinoma maintaining stable disease by using anti-vascular endothelial growth factor receptor antibody after the exacerbation of psoriasis due to small-molecule kinase inhibition (2020) (1)
- Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma in SVR achieved hepatitis C patients with interferon-free treatment (2018) (1)
- The impact of skeletal muscle loss for hepatocellular carcinoma treated with lenvatinib. (2020) (1)
- [A triple combination therapy of simeprevir (SM), pegylated-interferon and ribavirin (PR) with chronic hepatitis C virus genotype 1 infection]. (2015) (1)
- Reply to: “Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using RVR” (2011) (1)
- P735 ASSOCIATION OF GENETIC POLYMORPHISMS WITH FIBROSIS PROGRESSION IN CHRONIC HEPATITIS C AFTER FAILURE OF INTERFERON THERAPY (2014) (1)
- A nationwide multicenter study in patients with unresectable hepatocellular carcinoma treated with lenvatinib in real world practice in Japan. (2019) (1)
- [A case of systemic amyloidosis with cholangiectasis diagnosed by liver biopsy]. (2013) (1)
- A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response (2021) (1)
- Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma (2010) (1)
- Cost-Effectiveness Modeling Study of boceprevir for the treatment of patients with genotype 1 chronic hepatitis C virus infection in Hong Kong (2013) (1)
- The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) in real-world practice in Japan: A nationwide multicenter study in Japan. (2019) (1)
- Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan (2021) (1)
- SAT-006-Efficacy of oral thrombopoietin receptor agonist lusutrombopag in chronic liver disease by underlying disease aetiology (2019) (1)
- Validation of magnetic resonance elastography plus fibrosis‐4 for significant fibrosis in nonalcoholic fatty liver disease (2022) (1)
- THU-150-Factors associated with treatment failure with SOF+RBV in patients with genotype 2 chronic hepatitis C and consideration of retreatment with GLE+PIB in patients not responding to SOF+RBV (2019) (1)
- Imaging diagnosis and molecular profiling of hepatocellular carcinoma. (2016) (1)
- Percutaneous microwave coagulation therapy for small hepatocellular carcinomas that were confirmed by computed tomograpy during arterial portography (1998) (1)
- Mutation in the Box a Increases the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection (2005) (1)
- [A case of advanced gastric cancer acquired long-term response two years or more by treatment with oral anticancer drug TS-1]. (2004) (1)
- Reply: To PMID 23564522. (2014) (1)
- [Ulcerative colitis developed after acute exacerbation of chronic hepatitis B]. (2002) (1)
- Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease (2019) (1)
- Impaired Brain Activity in Cirrhotic Patients With Minimal Hepatic Encephalopathy: Evaluation by Near Infrared Spectroscopy (2011) (1)
- PF697 LUSUTROMBOPAG IS A SAFE AND EFFICACIOUS TREATMENT OPTION FOR THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING PLANNED INVASIVE PROCEDURES: INTEGRATED ANALYSIS OF TWO PHASE 3 TRIALS (2019) (1)
- Hepatic iron accumulation is an independent risk factor for the development of hepatocellular carcinoma after interferon therapy in patients with chronic hepatitis C (2001) (1)
- [Primary biliary cirrhosis among siblings with familial clustering of incidences of antimitochondrial antibody]. (1983) (1)
- Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study. (2023) (1)
- Focal hepatocellular necrosis and portal lymphocytic infiltration of the liver in chronic alcoholics: Histopathological study of 40 liver biopsies (1994) (1)
- P0381 : Clinical impact of achieving sustained virological response in hepatitis C virus-infected patients with early stage hepatocellular carcinoma (2015) (1)
- 690 SUPPRESSION OF ALPHA-FETOPROTEIN BY INTERFERON THERAPY REDUCES THE RISK OF HEPATOCARCINOGENESIS IN PATIENTS WITH CHRONIC HEPATITIS C (2012) (0)
- Factors associated with rapid fibrosis progression. (2015) (0)
- 1128 PREDICTION MODEL OF ANEMIA USING ITPA GENOTYPE IDENTIFIES PATIENTS AT HIGH RISK OF ANEMIA AND TREATMENT FAILURE WITH PEGYLATED-INTERFERON PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C (2012) (0)
- Hepatitis B surface antigen reduction by switching from long-term preceding nucleoside/nucleotide analog administration to pegylated interferon or tenofovir (2018) (0)
- Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan (2023) (0)
- Progress in Virological Response in the Difficult-to-Treat Patients with Genotype 1 Hepatitis C Virus ( HCV ) Infection and Factors Correlated (2014) (0)
- 1016 Lusutrombopag Is a Safe Treatment Option for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Invasive Procedure: Pooled Safety Analysis From 3 Studies (2019) (0)
- A case of Endoscopic Submucosal Dissection for a carcinoid tumor of the duodenum (2011) (0)
- [Present status of the treatment of chronic hepatitis C in Japan compared from Western countries]. (2004) (0)
- Subject Index Vol. 78, Suppl. 1, 2010 (2010) (0)
- Differences of liver membrane antibody frequency in alcoholic liver disease (1988) (0)
- Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis (2023) (0)
- New diagnostic method for hepatic steatosis using attenuation measurement by B mode ultrasound: Comparison with controlled attenuation parameter (2018) (0)
- Overexpression of interferon क-inducible protein 10 in the liver of autoimmune hepatitis (2000) (0)
- Clinicopathological characteristics and genetic background in Japanese elderly patinets with autoimmne hepatiytis (1994) (0)
- General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy (2022) (0)
- Impact of insulin resistance on levels of aminotransferases and γ-glutamyltranspeptidase in a general population (2003) (0)
- Hepatic Iron Accumulation and Incidence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C (2003) (0)
- Clinical trial of percutaneous radio frequency ablation therapy by two-step insertion method using VirtuTRAXTM instrument navigator (2013) (0)
- Sa1495 - Hbeag Loss and Seroconversion Predictors by Baseline Clinical Features and Viral Deep Sequencing of Treatment with Tenofovir Alafenamide Fumarate (TAF) or Tenofovir Disoproxil Fumarate (TDF) after 144 Weeks (2018) (0)
- Mechanisms and Treatment for Muscle Cramps in Liver Cirrhosis (2019) (0)
- 468 DATA MINING MODEL FOR IDENTIFICATION OF PATIENTS AT HIGH RISK FOR HEPATOCELLULAR CARCINOMA AFTER ERADICATION OF HEPATITIS C (2013) (0)
- JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B (2009) (0)
- Progress of antiviral therapy for hepatitis C virus infection (2015) (0)
- [A case of recurrent muscle spasms with marked elevation of serum creatine phosphokinase activity during the treatment of hyperthyroidism with methylmercaptoimidazole (author's transl)]. (1982) (0)
- The Association between Pnpla3 Polymorphisms and Fibrosis Progression and Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis C (2016) (0)
- Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab (2022) (0)
- Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study. (2020) (0)
- P982 MULTIDISCIPLINARY TREATMENTS IMPROVE SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: ANALYZING THE SURVIVAL RATE OF PATIENTS AFTER SORAFENIB ADMINISTRATION (2014) (0)
- A multicenter observational study of lenvatinib for unresectable hepatocellular carcinoma in Japan. (2021) (0)
- Issues in need for a solution among patients with successful eradication of hepatitis C virus. (2016) (0)
- [A case of cavernous hemangioma of the jejunum manifested by repeated melena]. (1991) (0)
- Abstract No. 617 Lusutrombopag reliably increases platelets regardless of baseline platelet counts in thrombocytopenic chronic liver disease patients undergoing planned invasive procedures: results of two phase 3 trials (2020) (0)
- FRI-506-A nationwide multicenter study in Japanese patients treated with lenvatinib in real world practice (2019) (0)
- Reply to Wang et al (2021) (0)
- [How to use viral genomic analysis in clinical practice: chronic hepatitis B and C]. (2006) (0)
- SAT-264-Prediction of hepatocellular carcinoma development using liver stiffness after sustained virological responses by magnetic resonance elastography in patients with chronic hepatitis C (2019) (0)
- Real world experience of lusutrombopag for thrombocytopenia in patients with liver cirrhosis (2018) (0)
- Reply: To PMID 24734314. (2014) (0)
- Reply (2014) (0)
- Risk factors for developing new nodules of hepatocellular carcinoma (HCC) in the liver apart from the primary subsegment after complete ablation by microwave or radiofrequency (2000) (0)
- P0786 : 100% SVR12 with ledipasvir/sofosbuvir±ribavirin for 12 weeks in Japanese patients with chronic genotype 1 hepatitis C virus who previously failed therapy with protease inhibitor + pegylated interferonα + ribavirin (2015) (0)
- A nationwide multicenter study of Japanese patients with unresectable hepatocellular carcinoma treated with regorafenib in real-world practice (2020) (0)
- Erratum to: Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B (2010) (0)
- Imaging Findings of Hepatocellular Carcinoma that Developed after HCV Eradication with Direct-Acting Antivirals (2019) (0)
- Initial and maintenance dose of sorafenib in female patients with advanced hepatocellular carcinoma should be modified to maximize therapeutic effect. (2018) (0)
- [Diagnosis and treatment under laparoscopy for chronic hepatitis C and hepatocellular carcinoma]. (2008) (0)
- Letter: predictive role of magnetic resonance elastography in chronic liver disease—still a long way to go. Authors' reply (2022) (0)
- P0753 : Genetic polymorphisms of IL28B and PNPLA3 are closely associated with fibrosis progression in chronic hepatitis C (2015) (0)
- A case of multiple hepatocellular carcinoma with inferior vena cava thrombosis which was resectable after multimodality therapy (2013) (0)
- Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma (2017) (0)
- Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group (2022) (0)
- Reply (2014) (0)
- 423 THE COMBINATION OF HBsAg AND HBV CORE-RELATED ANTIGEN (HBcrAg) MEASUREMENT IS USEFUL FOR DISCRIMINATING HBeAg NEGATIVE INACTIVE CARRIER AND EVALUATING THE RISK OF HCC (2013) (0)
- [Prevention of adverse effects in ribavirin and interferon combination therapy]. (2004) (0)
- Laparoscopic radiofrequency ablation using a sector ultrasonic probe for hepatocelular carcinoma on the liver surface (2002) (0)
- Clinical utility of comprehensive genomic profiling in patients with unresectable primary liver cancer. (2023) (0)
- Thanking All Peer Reviewers. (2015) (0)
- Predictors of HBeAg loss and seroconversion by baseline clinical features and viral deep sequencing after 144 weeks of treatment with Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate (2018) (0)
- P752 GENETIC POLYMORPHISM IN PNPLA3 GENE IMPACTS DISEASE PROGRESSION AND HEPATOCELLULAR CARCINOMA DEVELOPMENT IN CHRONIC HEPATITIS C (2014) (0)
- Altered gene expression in the liver of primary biliary cirrhosis (2000) (0)
- How to improve virological sustained response rate by interferon therapy for patients with chronic hepatitis C (2001) (0)
- P553 ELASTIC FIBER ACCUMULATION ESTIMATED BY A NOVEL AUTOMATED COMPUTATIONAL ANALYSIS AS A SIGNIFICANT PREDICTING FACTOR FOR THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (2014) (0)
- Fibrosis and fibrogenesis (2015) (0)
- PREDICTION OF RESPONSE TO PEGYLATED-INTERFERON FOR CHRONIC HEPATITIS C: IMPACT OF SNPS NEAR THE IL28B GENE AND MUTATIONS IN THE ISDR OF HCV REVEALED BY DATA MINING ANALYSIS (2010) (0)
- Panel discussion: Management of hepatocellular carcinoma (2009) (0)
- The impact of relative dose intensity on overall and progression-free survival during cabozantinib therapy for unresectable hepatocellular carcinoma. (2023) (0)
- 687 PROGNOSIS OF RUPTURED HEPATOCELLULAR CARCINOMA: IMPACT ON TUMOR STAGING SYSTEM BASED ON A NATIONWIDE SURVEY (2012) (0)
- P-72 Viral genomic features of asymptomatic HCV carriers comparing with chronic hepatitis C (1995) (0)
- Prediction Model with HLA-A*33:03 Reveals Number of Days to Develop Liver Cancer from Blood Test (2023) (0)
- PCN188 - ASSESSING THE ROBUSTNESS OF A COST-EFFECTIVENESS ANALYSIS OF LENVATINIB VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN JAPAN (2018) (0)
- The efficacy and safety of lenvatinib in patients with intermediate-stage hepatocellular carcinoma: A nationwide multicenter study in Japan. (2020) (0)
- 406 – Chronic Hbv Patients Who Switched to Tenofovir Alafenamide (TAF) After Either 2 Or 3 Years of Prior Tenofovir Disoproxil Fumarate (TDF) Treatment Demonstrated Improvement in Bone and Renal Safety (2019) (0)
- Predictive value of changes in plasma vascular endothelial growth factor at eight weeks after lenvatinib administration in patients with unresectable hepatocellular carcinoma. (2020) (0)
- Subject Index Vol. 48, 2005 (2005) (0)
- Lenvatinib as an Initial Treatment in Patients with Intermediate-stage Hepatocellular Carcinoma Beyond up-to-seven Criteria and Child-Pugh A Liver Function: A Proof-of-Concept Study (2019) (0)
- A case of acute severe hepatitis B caused by an HBV-Ae strain transmitted from her male sexual partner who also contracted acute hepatitis three months before (2005) (0)
- [Epithelioid hemangioendothelioma of the liver diagnosed by laparoscopy guided biopsy]. (2008) (0)
- 499 VERY-EARLY VIRAL RESPONSE (WEEK-1) TO TRIPLE THERAPY WITH TELAPREVIR, PEG-INTERFERON AND RIBAVIRIN PREDICTS EXTENDED-RVR AND TREATMENT OUTCOMES IN PATIENTS WITH HCV GENOTYPE 1 (2013) (0)
- Simple blood test criteria for non-cirrhosis plus age and post-treatment AFP rule-out the risk of hepatocellular carcinoma development after SVR (2020) (0)
- Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection (2022) (0)
- Identification of suppressed genes in human hepatocellular carcinoma by suppression subtractive hybridization (2000) (0)
- Factors associated with efficacy of retreatment with grecaprevir/ pibrentasvir therapy in prior DAA failed patients - nationwide multicenter study in Japan (2020) (0)
- Clinical Significance of Screening of Serum HIV Antibody Prior to Gastrointestinal Endoscopy (2000) (0)
- [Combination therapy of interferon plus ribavirin for chronic hepatitis C]. (2004) (0)
- [Clinico-pathological characteristics of chronic active hepatitis (non-B, non-lupoid type) (author's transl)]. (1981) (0)
- A case of a Japanese patient with delta hepatitis improved with interferon treatment. (1995) (0)
- Contents Vol. 35, 2017 (2017) (0)
- Contents Vol. 48, 2005 (2005) (0)
- The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase III trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma: A nationwide multicenter study in Japan (2019) (0)
- Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C (2014) (0)
- Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients (2021) (0)
- [Clinical characteristics of the hepatocellular carcinoma in alcoholic liver disease]. (2015) (0)
- THU-159-Real-world efficacy of elvasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group (2019) (0)
- Ramucirumab for HCC patients who experienced two or more systemic therapy: A multicenter study. (2022) (0)
- 498 Efficacy and safety of entecavir in Japanese adult patients with incomplete response to current lamivudine treatment: A phase II clinical trial (2006) (0)
- Contents Vol. 32, 2014 (2014) (0)
- Update strategy for the treatment of chronic hepatitis C. (2014) (0)
- A clinicopathological study of female patients with alcoholic liver disease. (1984) (0)
- [Various clinical conditions after successful eradication of hepatitis C virus]. (2018) (0)
- Clinical Results of Radiotherapy That Targeted for Tumor Thrombi from Hepatocellular Carcinoma: A Multicenter Retrospective Study (2020) (0)
- Reply to Methodological issues on prediction of hepatocellular carcinoma after sustained virological responses (2019) (0)
- Comparison of the prognosis between non-viral HCC and viral HCC (2018) (0)
- Utility of Ultrasound-Guided Attenuation Parameter for the Quantification of Steatosis with Reference to MRI-Based Proton Density Fat Fraction: A Multicenter, Prospective Study (2021) (0)
- Drug use-results survey of ombitasvir/paritaprevir/ritonavir coformulated tablet in patients with genotype 1 chronic hepatitis C with or without compensated cirrhosis (2021) (0)
- A case of endoscopic submucosal dissection for gastrointestinal stromal tumor located mainly in submucosa (2009) (0)
- 375 GENERATION OF THE PREDICTION MODELS FOR THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B AND EXTERNAL VALIDATION BY INDEPENDENT COHORTS (2011) (0)
- COMPARISON OF DISTRIBUTION OF HCV-RNA IN THE LIVER TISSUE AND PERITONEOSCOPIC FINDINGS IN PATIENTS WITH ANTI-HCV POSITIVE CHRONIC LIVER DISEASES (1993) (0)
- Improvement of response rate to IFN by patient-selection through testing genotypes and NS5A AA2209-2248 of HCV RNA before therapy in patients with chronic hepatitis C (1998) (0)
- External validation of clinical scoring system for the prediction of hepatocellular carcinoma in chronic hepatitis B treated by nucleotide/nucleoside analogue (2018) (0)
- 1041 OUTCOMES OF RADIOFREQUENCY ABLATION FOR HYPOVASCULAR HEPATOCELLULAR CARCINOMAS (2012) (0)
- IDDF2021-ABS-0077 Efficacy and safety of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in east asian chronic hepatitis B patients following 5-years of treatment (2021) (0)
- PF702 USE OF THE THROMBOPOIETIN RECEPTOR AGONIST LUSUTROMBOPAG FOR THROMBOCYTOPENIA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING PLANNED INVASIVE PROCEDURES: INTEGRATED ANALYSIS OF 2 TRIALS (2019) (0)
- [109th Scientific Meeting of the Japanese Society of Internal Medicine: educational lecture: 7. Cutting edge of the treatment for viral hepatitis]. (2012) (0)
- [Hepatitis B viral mutation and its clinical significance]. (2004) (0)
- Distribution of amino acid mutations in the NS5A region and interferon sensitivity in chronic hepatitis C (1998) (0)
- Hepatitis B Surface Antigen Reduction by Switching from Long-term Nucleoside/nucleotide Analog Administration to Pegylated Interferon Short running title: Sequential PEG-IFN after long-term NA (2017) (0)
- Evaluation of the Outcome after Transarterial Chemoembolization; Refinement of Barcelona Clinic Liver Cancer Stage-B from Eastern Point of View (2016) (0)
- 902 LONG-TERM EFFICACY OF NUCLEOS(T)IDE ANALOGS AND CLINICAL USEFULNESS OF HIGHLY SENSITIVE HBV-DNA QUANTIFICATION IN PREDICTING LAMIVUDINE-RESISTANT HBV (2009) (0)
- Front & Back Matter (2012) (0)
- HLA-DR2陽性,DR4陰性であった,高齢者の自己免疫性肝炎の2例 (1996) (0)
- Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial (2019) (0)
- Title : Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia Short title : Avatrombopag before procedures in CLD (2018) (0)
- Letter: association of laboratory indexes and magnetic resonance elastography‐associated liver stiffness with complications and mortality—authors' reply (2022) (0)
- Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma. (2010) (0)
- 441 THE ITPA GENOTYPE CORRELATES WITH HEMOLYTIC ANEMIA AND OUTCOME AFTER TREATMENT WITH PEGYLATED-INTERFERON AND RIBAVIRIN IN GENOTYPE IB CHRONIC HEPATITIS C (2011) (0)
- Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy (2023) (0)
- Abstract No. 615 Lusutrombopag is a safe and efficacious treatment option for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures: integrated analysis of two phase 3 trials (2020) (0)
- A prospective cohort study using a Japanese nationwide survey to evaluate the therapeutic effects of surgery and percutaneous ablation for hepatocellular carcinoma. (2012) (0)
- The efficacy of molecular targeted therapies after atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC) in Japan (2022) (0)
- FRI-158-Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment (2019) (0)
- Superparamagnetic iron oxide-enhanced magnetic resonance imaging is a beneficial modality for early diagnosis of hepatocellular carcinoma. A comparison with the vascular characterization by CT arteriography and CT arterioportography (2000) (0)
- Front & Back Matter (2012) (0)
- Amino acid sequence of putative dsRNA-dependent protein kinase-eukaryotic initiation factor 2A phosphorylation homology domain of hepatitis C virus and interferon sensitivity (2000) (0)
- Use of noninvasive biomarkers to assess fibrosis regression in cirrhotic patients during nucleos(t)ide therapy (2018) (0)
- Mutagenic effect of ribavirin in NS5A and NS5B regions and response to inteferon/ribavirin combination therapy in patients with chronic hepatitis C (2003) (0)
- [Antiviral effect of carnitine for chronic hepatitis or liver cirrhosis patients]. (2015) (0)
- 974 DIAGNOSTIC ALGORITHM FOR HEPATOCELLULAR CARCINOMA (HCC) IN HYPOVASCULAR NODULE OF THE LIVER; A MULTICENTER NATIONWIDE STUDY (2011) (0)
- Is the incidence of intrahepatic multicentric recurrence of hepatocellular carcinoma more frequent in “the carcinogenic stage” than in liver cirrhosis? (2003) (0)
- Simple algorithm to narrow down the candidates to receive echocardiography in patients with chronic liver disease for suspected pulmonary hypertension (2022) (0)
- Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma (2018) (0)
- Polymorphism analysis of the CD81 putative viral receptor in relation to various phases of hepatitis C virus infection (2000) (0)
- Mo1055 Clinical Features Associated With Radiological Response to Sorafenib Therapy for Unresectable Hepatocellular Carcinoma; A Multicenter Study in Japan (2014) (0)
- A case of carcinoid tumor of depressed typed with white mucosa (2012) (0)
- Identifying dilated vessels by magnifying endoscopy with narrow-band imaging : prediction of minute submucosal invasion in two cases of early gastric cancer (2021) (0)
- Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy (2022) (0)
- [Analysis of replicating hepatitis C virus quasispecies in hepatocellular carcinoma tissues]. (2004) (0)
- Prediction of Hepatocellular Carcinoma after Successful Eradication of Hepatitis C by Simple and Readily Available Factors: Nationwide Multicenter Study by Japanese Red Cross Liver Study Group (2016) (0)
- The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy (2022) (0)
- Early Experience of Ramucirumab Therapy in Japanese Patients With Unresectable Hepatocellular Carcinoma in Real-World Practice (2020) (0)
- Abstract No. 616 Lusutrombopag is a safe treatment option for thrombocytopenia in patients with chronic liver disease undergoing a planned invasive procedure: pooled safety analysis from three studies (2020) (0)
- P571 GADOLINIUM ETHOXYBENZYL DIETHYLENETRIAMINEPENTAACETIC ACID MAGNETIC RESONANCE IMAGING AND CONTRAST ENHANCED ULTRASONOGRAPHY WITH SONAZOID AS PART OF THERAPEUTIC STRATEGIES FOR SMALL NONHYPERVASCULAR HEPATIC NODULAR LESIONS (2014) (0)
- Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients (2019) (0)
- Serum hepatocyte growth factor (HGF) is a potential marker for baseline liver function and its early deterioration in patients treated with sorafenib (2017) (0)
- 270 PREDICTIVE MODEL OF RESPONSE TO PEGINTERFERON IN CHRONIC HEPATITIS C: IMPACT OF MUTATIONS IN ISDR AND CORE REGION REVEALED BY CLASSIFICATION AND REGRESSION TREE ANALYSIS (2010) (0)
- 1037 PREDICTING FACTORS OF LOCAL RECURRENCE AFTER CURATIVE PERCUTANEOUS RADIOFRECUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA (2012) (0)
- Serum Wisteria Floribunda agglutinin-positive sialylated mucin 1 as a biomarker of hepatic progenitor cell/biliary features in hepatocellular carcinoma and of recurrence after curative therapy (2017) (0)
- 1038 DECREASE OF PLASMA VEGF LEVEL WITHIN 2 MONTHS AFTER SORAFENIB ADMINISTRATION PREDICTS TREATMENT EFFICACY AND PROGNOSIS IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (2012) (0)
- Clinical results of radiotherapy for hepatocellular carcinoma with tumor thrombosis. (2020) (0)
- A Case of Cardiac Cancer Invading the Lower Esophagus : Treatment with the Ultraflex Esophageal Prosthesis (1996) (0)
- [Prediction of response to peginterferon and ribavirin therapy for chronic hepatitis C analyzed by data mining method]. (2011) (0)
- Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma (2023) (0)
- Identification of differentially expressed genes in gastric adenoma and cancer using suppression subtractive hybridization (2000) (0)
- SAT-268-Non-invasive prediction of gastroesophageal varies by serum wisteria floribunda agglutinin positive Mac-2 binding protein and FIB-4 index in chronic hepatitis C (2019) (0)
- Disappearance of HBcAG in the liver is a clinically useful marker for discontinuation of lamivudine therapy in patients with chronic hepatitis B (1998) (0)
- A Survival Case of Aortoduodenal Fistula with Upper Gastrointestinal Hemorrhage (2000) (0)
- Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B (2022) (0)
- Clinical impact of the changes of muscle volume during various systemic therapies in patients with unresectable hepatocellular carcinoma. (2022) (0)
- [Prediction of response to peg-interferon plus ribavirin therapy for chronic hepatitis C]. (2011) (0)
- Distinctive magnetic resonance imaging findings of hepatocellular carcinoma after hepatitis C virus eradication with direct-acting antivirals (2020) (0)
- [Treatment for hepatitis C under hemodialysis]. (2015) (0)
- 241 REDUCING ALPHA-FETOPROTEIN WITH INTERFERON THERAPY SUPPRESSES HEPATOCARCINOGENESIS IN HEPATITIS C VIRUS-INFECTED PATIENTS WHO ARE VIROLOGICAL RESPONDERS AND NON-RESPONDERS (2010) (0)
- THE CHARACTERISTIC FINDINGS AND DIAGNOSTIC SIGNIFICANCE OF LAPAROSCOPY IN FIVE CASES OF HEPATIC AMYLOIDOSIS (1982) (0)
- Usefulness of newly proposed albumin-bilirubin grade and its modification -Japan nationwide survey (2018) (0)
- PF698 LUSUTROMBOPAG RELIABLY INCREASES PLATELETS REGARDLESS OF BASELINE PLATELET COUNTS IN THROMBOCYTOPENIC CHRONIC LIVER DISEASE PATIENTS UNDERGOING PLANNED INVASIVE PROCEDURES: RESULTS OF 2 PHASE 3 TRIALS (2019) (0)
- Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group (2023) (0)
- FRI-181-Efficacy and safety of switching therapy from tenofovir disoproxil fumarate to tenofovir alafenamide for hepatitis B virus infection (2019) (0)
- [Plasma levels of human atrial natriuretic polypeptide in patients with liver cirrhosis]. (1986) (0)
- 65 PEGINTERFERON AND RIBAVIRIN THERAPY IMPROVE PROGNOSIS IN PATIENTS AFTER CURATIVE TREATMENT OF HEPATOCELLULAR CARCINOMA-ASSOCIATED HEPATITIS C (2009) (0)
- Rabeprazole and amoxicillin for 2 weeks are similarly efficacious as triple therapy for the eradication of Helicobacter pylori in peptic ulcer patients (2000) (0)
- Two case reports of primary biliary cirrhosis associated with interstitial nephritis. (1999) (0)
- 1027 KUPFFER IMAGE BY CONTRAST-ENHANCED US WITH SONAZOID IS USEFUL FOR EVALUATING HYPOVASCULAR LIVER NODULES DEPICTED AS HYPOINTENSE IN THE HEPATOBILIARY PHASE OF GD-EOB-DTPA-ENHANCED MRI (2011) (0)
- 1347 A PROSPECTIVE STUDY ON THE CLINICAL IMPACT OF VIRAL ERADICATION AND IL-28B GENOTYPE ON PEG-INTERFERON AND RIBAVIRIN THERAPY AFTER CURATIVE TREATMENT FOR HEPATOCELLULAR CARCINOMA (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Namiki Izumi?
Namiki Izumi is affiliated with the following schools:
